Binding Database

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.

Genomics Institute Of The Novartis Research Foundation

Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.

Shanghaitech University

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.

Jinan University

Discovery of a potent dual ALK and EGFR T790M inhibitor.

Harvard Medical School

Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).

Zhejiang University

Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.

Dana-Farber Cancer Institute

First macrocyclic 3

Taibah University